Results 61 to 70 of about 57,705 (278)

Comparative study of the efficacy of tamoxifen and aromatase inhibitors among breast cancer patients at Kenyatta National Hospital

Journal of the Egyptian National Cancer Institute
Background Aromatase inhibitors have demonstrated superior outcomes compared to tamoxifen in various studies. However, research in Africa, including Kenya, where breast cancer mortality rates are disproportionately high, is lacking.
Henry Gachoki Macharia, Amsalu Degu
doaj   +1 more source

Manejo farmacológico da baixa estatura: o papel dos inibidores da aromatase Pharmacological management of children with short stature: the role of aromatase inhibitors

Jornal de Pediatria, 2007
OBJETIVO: Revisão sobre o uso de inibidores de aromatase, uma nova modalidade terapêutica em pacientes com baixa estatura, numa tentativa de evitar o avanço rápido da idade óssea, dependente da produção estrogênica, mesmo no sexo masculino.
Durval Damiani, Daniel Damiani
doaj   +1 more source

Celecoxib in breast cancer prevention and therapy. [PDF]

, 2018
Breast cancer has a high incidence worldwide. The results of substantial studis reveal that inflammation plays an important role in the initiation, development, and aggressiveness of many malignancies. The use of celecoxib, a novel NSAID, is repetitively
Cao, Wei, Hao, Qiongyu, Li, Jieqing, Vadgama, Jaydutt V, Wu, Yong   +4 more
core  

Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy [PDF]

, 2014
Background: After breast-conserving radiation therapy most patients experience acute skin toxicity to some degree. This may impair patients' quality of life, cause pain and discomfort. In this study, we investigated treatment and patient-related factors,
De Langhe, Sofie, De Neve, Wilfried, De Ruyck, Kim, DE SCHEPPER, ELINE, Gilsoul, Monique, MULLIEZ, THOMAS, Remouchamps, Vincent, Thierens, Hubert, van Greveling, Annick, Veldeman, Liv   +9 more
core   +2 more sources

Metastatic Cutaneous Adnexal Carcinoma of the Head and Neck With Durable Response to an Aromatase Inhibitor Combined With a Cyclin‐Dependent Kinase 4/6 Inhibitor

Head &Neck, EarlyView.
ABSTRACT Background Cutaneous adnexal carcinomas are a very rare group of cancers arising from appendageal structures of the skin. More than half occur in the head and neck region. No standard treatments exist for metastatic disease. Methods A 48‐year‐old postmenopausal female presented with an enlarging scalp lesion.
Nilesh Kapoor, Manasa Narasimman, Travis Vandergriff, Amy L. Jones   +3 more
wiley   +1 more source

Discovery and Evaluation of Novel Sulfonamide Derivatives Targeting Aromatase in ER+ Breast Cancer

Pharmaceuticals
Background: Third-generation aromatase inhibitors (CYP19A1) are the mainstay of treatment for estrogen-receptor-positive breast cancer. This is because estrogen is required for cancer growth in approximately 70% of patients with this condition.
Barbara De Filippis, Mariangela Agamennone, Alessandra Ammazzalorso, Rosa Amoroso, Letizia Giampietro, Cristina Maccallini, Begüm Nurpelin Sağlık, Chiara De Simone, Mariachiara Zuccarini, Zafer Asım Kaplancıklı, Marialuigia Fantacuzzi   +10 more
doaj   +1 more source

Tadalafil modulates aromatase activity and androgen receptor expression in a human osteoblastic cell in vitro model [PDF]

, 2016
Purpose Phosphodiesterase type-5 inhibitor (PDE5i) tadalafil administration in men with erectile dysfunction is associated with increased testosterone/estradiol ratio, leading to hypothesize a potential increased effect of androgen action on target ...
Aversa, Antonio, Bimonte, V. M., Fittipaldi, Simona, Francomano, Davide, Greco, E. A., Lenzi, Andrea, Migliaccio, S., Papa, V., Wannenes, F.   +8 more
core   +1 more source

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

International Journal of Cancer, EarlyView.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke‐Heckenkamp, Diana Lüftner, Frederik Marmé, Marion van Mackelenbergh, Beate Rautenberg, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Elena Kisseleff, Christina Pfister, Claudia Quiering, Christian Roos, Achim Wöckel   +20 more
wiley   +1 more source

Impact of aromatase inhibitors on thyroid function in postmenopausal women with early-stage breast cancer: a prospective controlled study

Cancer Treatment and Research Communications
Purpose: Aromatase inhibitors are commonly used in adjuvant therapy for breast cancer. However, their impact on thyroid function remains unclear. This study aimed to evaluate thyroid function in postmenopausal women with oestrogen-receptor-positive early-
Djordje Marina, August Nielsen, Kristian Buch-Larsen, Michael Andersson, Åse Krogh Rasmussen, Peter Schwarz   +5 more
doaj   +1 more source

Computational method for aromatase-related proteins using machine learning approach.

PLoS ONE, 2023
Human aromatase enzyme is a microsomal cytochrome P450 and catalyzes aromatization of androgens into estrogens during steroidogenesis. For breast cancer therapy, third-generation aromatase inhibitors (AIs) have proven to be effective; however patients ...
Muthu Krishnan Selvaraj, Jasmeet Kaur
doaj   +1 more source